Vanguard Group Inc Cognition Therapeutics Inc Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding CGTX
# of Institutions
45Shares Held
6.58MCall Options Held
0Put Options Held
0-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$970,3650.02% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$220,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA324KShares$142,4020.0% of portfolio
-
Cm Management, LLC250KShares$110,0000.1% of portfolio
-
American Financial Group Inc205KShares$90,2000.04% of portfolio
About COGNITION THERAPEUTICS INC
- Ticker CGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,710,700
- Market Cap $9.99M
- Description
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...